ArticleAntimicrobial agents and chemotherapy2024
Nationwide genome surveillance of carbapenem-resistant
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- CRISPR-Cas systems in combating antimicrobial resistance: which system to choose? A systematic review.World journal of microbiology & biotechnology · 2025Pooled it
- Global prevalence and antibiotic resistance profiles of carbapenem-resistantFrontiers in microbiology · 2025Pooled it
- Article
- Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026Review
- Genomic analysis of intrahospital transmission of carbapenem-resistant Gram-negative bacteria: a multicentre study in Japan.Microbial genomics · 2026Article
- Molecular evolution and mechanisms underlying extremely high-level carbapenem resistance in the emerging CRPA clone ST1976.BMC microbiology · 2026Article
- Glnk Mediates Carbapenem Resistance Through the NtrB/NtrC-OprD Regulatory Pathway inPathogens (Basel, Switzerland) · 2026Article
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Antimicrobial resistance phenotypes, disinfectant susceptibility, and resistance-associated gene detection in carbapenem-resistant Pseudomonas aeruginosa from two tertiary hospitals in Urumqi, China.Frontiers in cellular and infection microbiology · 2026Article
- Within-host adaptation mutations associated with persistent colonization ofFrontiers in cellular and infection microbiology · 2026Article
- Molecular epidemiological association between antimicrobial resistance characteristics and type III secretion system in carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Optimization of cefepime dosage regimens forGlobal health & medicine · 2025Article
- First nationwide survey onAntimicrobial agents and chemotherapy · 2025Article
- Specific variants inMicrobiology spectrum · 2025Article
- Predicting carbapenem-resistant Pseudomonas aeruginosa infection risk using XGBoost model and explainability.Scientific reports · 2025Article
- Antibiotic-ResistantMicroorganisms · 2025Review
- Companions in antimicrobial resistance: examining transmission of common antimicrobial-resistant organisms between people and their dogs, cats, and horses.Clinical microbiology reviews · 2025Review
- Article
- High-riskHeliyon · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Japan is a country with an approximate 10% prevalence rate of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.